A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
University of Texas Southwestern Medical Center
Albert Einstein College of Medicine
SWOG Cancer Research Network
SWOG Cancer Research Network
SWOG Cancer Research Network
Northwestern University
National Cancer Institute (NCI)
UNC Lineberger Comprehensive Cancer Center
Vanderbilt-Ingram Cancer Center
Memorial Sloan Kettering Cancer Center